Table 3.
Modelled resource use and costs for the base-case scenario. Also shown are ranges used for the probabilistic sensitivity analysis
| Parameter | Base case value | Sensitivity analysis range | References |
|---|---|---|---|
| Resource use | |||
| Pad utilisation | |||
| Incontinence level 1 | 0.17 | 0.150–0.198 | SCORPIO [15] |
| Incontinence level 2 | 0.75 | 0.687–0.817 | |
| Incontinence level 3 | 1.38 | 1.282–1.486 | |
| Incontinence level 4 | 1.89 | 1.745–2.039 | |
| Incontinence level 5 | 3.34 | 3.167–3.511 | |
| GP consultations | 1 visit at start and at every switch | 0–2 | Expert opinion |
| Specialist consultations | 1.5 visits at start and at every switch | 1–3 | Cardozo et al. [31]/assumption |
| BTX injectionsa | 0.17 per month | 0–0.34 | Expert opinion |
| Costs | |||
| Monthly acquisition cost | |||
| Mirabegron 50 mg | £29.40 | BNF 2011/12 [39] | |
| Tolterodine ER 4 mg | £28.01 | BNF 2011/12 [39] | |
| Solifenacin 5 mg | £28.00 | BNF 2011/12 [39] | |
| GP consultation | £36.00 | PSSRU 2010 [40] | |
| Specialist visit | £96.00 | NHS payment 2010–2011 | |
| BTX injection/reinjection | £1,158/£964 | Nottingham Urology Group [41] | |
| Incontinence pad | £0.16 | AgeUK [42] | |
BNF British National Formulary, BTX botulinum toxin, GP general practitioner, PSSRU Personal Social Services Research Unit
aFollowing successful first injection